Stock Market Reviews

AXSM (Axsome Therapeutics, Inc.) News

Get the latest news, insights, and market updates on AXSM (Axsome Therapeutics, Inc.). Explore the news page 5 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• US Equities Fall Intraday as Losing Streak Grows But Wall Street Eyes 2025 Gains
  US equity benchmarks were lower intraday with 2025 drawing to a close amid a four-day run of losses,
  Dec 31, 2025 - $AXSM
• US Equities Fall in Final 2025 Session; Indexes Still Post Solid Annual Gains
  US equity benchmarks fell Wednesday in the final session of 2025 as stock gauges still logged solid
  Dec 31, 2025 - $AXSM
• Top Midday Stories: Nvidia Approaches TSMC in Quest to Boost H200 Chip Production; Corcept Faces Setback From FDA on Hypertension Drug
  All three major US stock indexes were down in late-morning trading Wednesday as the year winds to a
  Dec 31, 2025 - $AXSM
• Sector Update: Health Care Stocks Softer Late Afternoon
  Health care stocks declined late Wednesday afternoon with the NYSE Health Care Index dropping 0.5% a
  Dec 31, 2025 - $AXSM
• Sector Update: Health Care Stocks Softer Wednesday Afternoon
  Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index and the State Stree
  Dec 31, 2025 - $AXSM
• Sector Update: Health Care Stocks Lean Lower Premarket Wednesday
  Health care stocks were leaning lower premarket Wednesday, with the State Street Health Care Select
  Dec 31, 2025 - $AXSM
• Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
  New Drug Application (NDA) submission on track for January 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has received formal pre-New Drug Application (NDA) meeting minutes from the U.S. Food and Drug Administration (FDA) supporting an NDA submission for AXS-12 in narcolepsy. AXS-12 (reboxetine) is a highly selective and pot
  Dec 31, 2025 - $AXSM
• Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
  FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026 NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s supplemental New Drug Application (NDA) for AXS-05 (dextromethorphan HBr and bupropion HCl) for the treatment
  Dec 31, 2025 - $AXSM
• Axsome's Application for Alzheimer's Side Effect Treatment Gets FDA Priority Review; Shares Soar
  Axsome Therapeutics (AXSM) shares surged Wednesday after saying its supplemental new drug applicatio
  Dec 31, 2025 - $AXSM
• Axsome Therapeutics Stock Jumps After FDA Grants Priority Review For Alzheimer's Agitation Drug
  Axsome stock jumped Wednesday after the biotech firm said its Alzheimer's disease agitation drug will get a priority review.
  Dec 31, 2025 - $AXSM